Literature DB >> 18596741

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis.

D Bowen, M J Groves, A K Burnett, Y Patel, C Allen, C Green, R E Gale, R Hills, D C Linch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18596741     DOI： 10.1038/leu.2008.173

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  49 in total

1.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Harry Erba; Peter Ouillette; Diane Roulston; Anjali Purkayastha; Judith Karp; Moshe Talpaz; Lisa Kujawski; Sajid Shakhan; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2010-08-20       Impact factor: 22.113

2.  CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Authors:  Leena Chaudhuri; Nicole D Vincelette; Brian D Koh; Ryan M Naylor; Karen S Flatten; Kevin L Peterson; Amanda McNally; Ivana Gojo; Judith E Karp; Ruben A Mesa; Lisa O Sproat; James M Bogenberger; Scott H Kaufmann; Raoul Tibes
Journal:  Haematologica       Date:  2013-10-31       Impact factor: 9.941

3.  Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Authors:  Betül Oran; Antonio M Jimenez; Marcos De Lima; Uday R Popat; Roland Bassett; Borje Andersson; Gautam Borthakur; Qaiser Bashir; Julianne Chen; Stefan O Ciurea; Elias Jabbour; Jorge Cortes; Partow Kebriaei; Issa F Khouri; Muzaffar H Qazilbash; Farhad Ravandi; Gabriela Rondon; Xinyan Lu; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

4.  Abnl(17p) in AML: who will guard the guardian?

Authors:  Minoo Battiwalla
Journal:  Blood       Date:  2014-05-08       Impact factor: 22.113

5.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Authors:  Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

Review 6.  Differential network analysis in human cancer research.

Authors:  Ryan Gill; Somnath Datta; Susmita Datta
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

Authors:  Aziz Nazha; Hagop M Kantarjian; Vijaya R Bhatt; Graciela Nogueras-Gonzalez; Jorge E Cortes; Tapan Kadia; Guillermo Garcia-Manero; Lynne Abruzzo; Naval Daver; Naveen Pemmaraju; Alfonso Quintas-Cardama; Farhad Ravandi; Michael Keating; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-22

8.  NPM1 deletion is associated with gross chromosomal rearrangements in leukemia.

Authors:  Roberta La Starza; Caterina Matteucci; Paolo Gorello; Lucia Brandimarte; Valentina Pierini; Barbara Crescenzi; Valeria Nofrini; Roberto Rosati; Enrico Gottardi; Giuseppe Saglio; Antonella Santucci; Laura Berchicci; Francesco Arcioni; Brunangelo Falini; Massimo Fabrizio Martelli; Constantina Sambani; Anna Aventin; Cristina Mecucci
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

9.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

Authors:  Tapan M Kadia; Preetesh Jain; Farhad Ravandi; Guillermo Garcia-Manero; Michael Andreef; Koichi Takahashi; Gautam Borthakur; Elias Jabbour; Marina Konopleva; Naval G Daver; Courtney Dinardo; Sherry Pierce; Rashmi Kanagal-Shamanna; Keyur Patel; Zeev Estrov; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

10.  TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.

Authors:  M Jasek; L P Gondek; N Bejanyan; R Tiu; J Huh; K S Theil; C O'Keefe; M A McDevitt; J P Maciejewski
Journal:  Leukemia       Date:  2009-09-17       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.